The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge. In this review we summarize the outcomes of the currently available treatment modalities and discuss emerging novel approaches.
Introduction
Leukaemic relapse following allogeneic SCT remains a major cause of treatment failure, occurring in up to 70% of patients. 1 Factors associated with an increased risk of disease relapse include, among others: lack of CR at transplant, use of reduced-intensity conditioning (RIC), older age and adverse cytogenetics. Without further treatment the survival time is very short. 2, 3 However, even with treatment, the outcome is generally poor and approaches remaining unstandardized, anecdotal and/or experimental.
There is a great deal of evidence to suggest that a significant part of the curative effect of an allogeneic transplant is immune mediated, that is GvL. Therefore the main strategies for managing relapsed disease aim to exploit this GvL effect in a number of ways. An alternate approach is to achieve disease control using re-induction chemotherapy and in many cases a combination of these two approaches is used. In most cases no direct comparison of the relative success of the different approaches is available and studies reporting various interventions are often small and/or from registry data.
We aim to review the approaches currently used, their relative success and to mention emerging novel approaches.
Presentation of relapse
Most cases of relapse of acute leukaemia following an allogeneic transplant present as overt bone marrow disease, often preceded by a fall in blood counts in an otherwise well individual. However, in up to a quarter of relapses in ALL and 13% in AML the relapse is extramedullary (EM). 3, 4 Although there may not be evidence of bone marrow involvement at presentation in these patients, this inevitably follows unless systemic treatment is instituted. In addition, there is a suggestion in some studies that the prognosis of patients with EM relapse of AML is less favourable than those who relapse in the bone marrow alone. 5 In the great majority of cases the relapse occurs in the patient's own cells (that is the original clone). However, in rare cases, relapse may occur in donor cells. 6, 7 This is an important consideration, and should be actively excluded, as certain treatment options are obviously not appropriate in this setting (for example donor leucocyte infusion (DLI) or second transplant using the same donor). Responses to other forms of treatment (for example chemotherapy) do not appear to differ significantly to those in patients with patient-derived leukaemia. In patients with donor-derived leukaemia, salvage therapy using a different donor for a second transplant may be successful. 7 
Predicting and preventing relapse
The use of minimal residual disease (MRD) monitoring to follow patients who are at a high risk of disease relapse post-transplant may allow interventions, such as the rapid tapering of immunosuppression (IS) or initiation of DLI, to be instituted prior to the development of overt relapse.
In ALL, there is evidence that MRD positivist both before [8] [9] [10] and after 11, 12 transplant can be predictive of disease relapse. In adults with Ph þ ALL, MRD following SCT is associated with a relapse probability which exceeds 90%. 13 In AML, molecular monitoring in those with particular chromosomal abnormalities (t(15:17), t(8:21) or inv16) 14, 15 may be used to predict relapse. In a recent study of 80 patients with ALL or AML, MRD was studied monthly using PCR for High VDJ or TCR in ALL and Wilms' tumour gene-1 copy number in AML.
Haematological relapse was significantly higher in MRDpositive patients. Furthermore MRD-positive patients given DLI had a significantly reduced relapse risk and improved 3-year survival. 16 New technologies to improve the detection of MRD are being investigated. 17 Mixed chimerism has been shown, in some studies, to predicted for disease relapse. [18] [19] [20] [21] [22] In particular, the use of subset chimerism (for example CD34 þ , CD33 þ , CD45 þ cells in AML or markers of the leukaemic phenotype in ALL) is reported to be a specific and reliable marker.
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Pre-emptive DLI, used to convert the patient to a full donor chimera has been associated with a reduction in the relapse rate.
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An alternative strategy to prevent relapse is the use of planned DLI (that is an integral part of the transplantation regimen) in patients predicted to be at a high risk of relapse. This has been implemented with some success, particularly in high-risk patients treated with T-cell depleted (TCD) conditioning regimens. [31] [32] [33] [34] [35] Immunosuppressant therapy is tapered rapidly and DLI commenced early (1-6 months) and then stopped when a degree of GvHD is present or when a set cell dose is reached.
Using this approach, the dose and timing of DLI are critical to achieve GvL without unacceptable rates of GvHD. An approach shown to effectively reduce GvHD in the setting of DLI is the use of an escalating dose schedule, starting with small numbers of T cells (10 5 CD3 þ cells/kg) and increasing at 2-3 monthly intervals. 36, 37 In addition, GvHD has been shown to be more common and severe following DLI from unrelated donors, 38 and it is recommended that lower doses be used in these patients (one log less T cells).
Finally pharmaceutical agents can be used in certain settings. For example, in Ph þ ALL, imatinib may be used peri-transplantation without additional toxicity. 39 Based on MRD status, imatinib has been used successfully in Ph þ ALL patients to improve disease-free survival. 13 In AML, hypomethylating agents have been investigated. These may induce leukaemic cell differentiation and increase immunogenicity and consequently potentially enhance the GvL effect. A phase I clinical dose finding study 40 included 12 patients with AML/myelodysplastic syndrome (MDS). Treatment with 5-azacytidine was started on day þ 42 at various doses. This was well tolerated with detectable levels of hypomethylation and there was no increased incidence of GvHD.
Treatment options for relapse
A major difficulty in interpreting the data from the reported studies is understanding how often different approaches are offered at individual centres and the proportion of patients receiving each, therefore biasing results. In addition it is not always clear on what basis differing treatments are offered to different individuals. For example, in some cases the use of a second allograft or DLI may be based on the availability of a donor. Certain interventions (for example cytokines) may be offered in a centre with the appropriate resources and/or expertise or in which a clinical trial is ongoing. Data from the The International Bone Marrow Transplant Registry (IBMTR) suggest that only 6% of patients who relapse following a sibling allograft for leukaemia receive a second transplant. 41 Such issues will be difficult to address. The restrictions imposed by financial considerations should also be taken into account. 42 The largest single centre report, 43 analysed 310 patients receiving allogeneic transplants for acute leukaemia. Of these, 100 patients relapsed, 28 with ALL and 72 with AML. The median survival was 303, 442, 84 and 51 days for those treated with second allograft, cytokines, DLI and chemotherapy/supportive care respectively (Figure 1 ). Overall the patients who received some form of immune therapy had a superior survival to those that did not.
Disease-directed treatment
Intensive chemotherapy ( þ adjuvant therapy). Complete remission rates, following re-induction chemotherapy, of between 40 and 60% have been reported in patients relapsing post-transplant, particularly if the relapse is late. However, responses achieved are usually short lived with survival after 2 years of less than 10%. 2, 3, 44 Novel reinduction strategies are required, these may include the use of Gemtuzumab oozagamicin (GO)-based regimens in AML or dasatinib in Ph þ ALL. 5-Azacytidine has also been used as a single agent in relapsed AML with some success. 45 These approaches are unlikely to be successful alone 43 but may be used to induce remission prior to other interventions such as DLI or a second allograft.
Additional strategies will be required in patients with EM relapse. 46 Localized radiotherapy may be utilized for individual lesions, however may not be feasible in patients with multiple EM sites of relapse, 47 and in addition does not seem to protect against leukaemic progression in the bone marrow. 5 In central nervous system relapses, intrathecal chemotherapy can be used. An attractive option in the setting of EM relapse may be the addition of GO, which may be particularly effective in patients with a low tumour burden. 47 Exploiting GvL Withdrawal of immunosuppression. Although withdrawal of IS has been seen to be effective in some patients with CML, 48 and although anecdotal reports of success in acute leukaemia exist, 49, 50 it is very unlikely that this alone will be sufficient to halt the course of a rapidly expanding malignant clone. It may be that this strategy could be of benefit in patients with early relapse detected by MRD monitoring.
Donor leucocyte infusions.
It is now well recognized that DLI can be given for the treatment of relapse in a number of diseases, to exploit the GvL effect and achieve remission. There is a clearly established role for DLI in relapsed CML and there are data suggesting that DLI have a promising role in relapse in many of the lymphoproliferative disorders. 38, [51] [52] [53] [54] [55] DLI to treat relapsed AML. Studies of DLI in AML from the 1990s reported CRs in 15-30% of patients. 56, 57 Even when CR is obtained, the length of remission in short-and long-term follow-up results suggested a survival of around 20% at 3 years. 58, 59 More recent studies report improved outcomes (Table 1) , particularly if risk groups are considered or re-induction chemotherapy given prior to DLI. A recent large study from the The European Blood and Marrow Transplant group (EBMT) Acute Leukaemia Working Party 60 analysed the outcome in patients who received DLI for relapsed leukaemia. Factors that they found to be associated with an increased survival after DLI were remission prior to DLI, a low tumour burden at relapse and female gender. Those in remission at DLI had a 2-year survival of 55%. The overall survival (OS) was 25% in those without remission, but female and with o35% blasts at relapse and 10% in all others. A study from Nottingham City Hospital 30 analysed the outcome in 17 patients with AML/MDS who relapsed following an RIC transplant. Of these, seven received DLI and ten did not. Of the seven receiving DLI, five remain alive and disease free between 147 and 826 days post-transplant. The two deaths in this group were due to relapse, compared to the group not receiving DLI where all 10 patients died due to relapse.
Data from 44 patients with relapsed AML following an unrelated donor transplant in the United Kingdom 61 showed a significant survival advantage for those receiving DLI. The survival at 2 years from relapse was 44% in those 21 patients who received DLI, compared to close to zero (four survivors followed up for less than 1 year) in those who did not receive DLI (Po0.0001).
Levine et al. 62 reported on 65 patients receiving DLI after cytarabine-based chemotherapy following relapse after an HLA-matched sibling allograft. While the CR rate was encouraging at 47%, the OS at 2 years was only 19% due to a high transplant-related mortality (TRM). Arellano et al. 43 showed that the inclusion of pre-DLI chemotherapy improved the median survival from 84 to 240 days. In both of these studies, an important factor impacting on the success of DLI was the time to relapse post-transplant (4six months and 4136 days, respectively).
Similar results were reported by Huff et al. 63 in 13 patients with relapsed AML treated with DLI, 7 of whom received salvage chemotherapy within the preceding month. The decision to give chemotherapy was based on the aggressiveness of the disease at relapse. The CR rate was 46%, with 31% of patients remaining in CR (median follow-up 1526 days). Deaths in these patients were due to a variety of causes including GvHD, and it was noted that the presence of GvHD (acute or chronic) was more likely to be associated with a disease response. Once again, in this study, the time to relapse after first transplant was a significant predictor of DLI success. Lee et al. 64 reported CR rates of over 80% following chemotherapy with six of eight patients surviving at the time of reporting. Finally, 2-year OS of 31% was reported in 16 AML patients. 65 A remission longer than 6 months post-transplant was associated with a significantly better OS.
DLI to treat relapsed ALL. Despite initial reports of success using DLI to treat relapsed ALL, 66 the success of this intervention has been a disappointment and remains largely anecdotal. 63, [67] [68] [69] This may be somewhat surprising, as in ALL there are a number of published studies [70] [71] [72] showing a strong association between a decrease in disease relapse in ALL patients who develop GvHD, suggesting that there is a strong GvL effect. A possible explanation for Table 1 The outcome reported in recent studies following donor leucocyte infusions for patients relapsing after an allograft Abbreviations: ALL ¼ acute lymphoblastic leukaemia; AML ¼ acute myelogenous leukaemia; MDS ¼ myelodysplastic syndrome; Unk ¼ unknown.
Relapsed leukaemia post-transplant BE Shaw and NH Russell this contradiction is that DLI in their current form are given too late (that is when frank leukaemia is already present) and are insufficient to halt the progress of the rapidly dividing clone. Arellano et al. 43 showed a longer survival in patients with ALL who developed de novo GvHD following DLI (P ¼ 0.013).
Large studies have reported poor OS of less than 15% at 3 years (Table 1) . In a European registry study, 43 patients with ALL had close to 0% survival at 2 years. 58 A North American registry study which included a similar number of patients 73 reported that a minority of patients went into CR and achieved a long-term disease-free survival. In this study DLI were given both within and without the context of intensive chemotherapy.
It is perhaps in ALL that the benefit of MRD monitoring and early intervention with DLI will be most apparent. 12 Modified DLI. Strategies to increase the success of DLI in these diseases include the modification of DLI in various ways. These aim either to enhance responsiveness (for example pharmacological agents) or to lessen toxicity (for example depletion of alloreactive cells). An extensive review is beyond the scope of this article, however some examples are given here.
Pharmaceutical agents such as 5-azacytidine and imatinib have been associated with remissions when used with DLI in patients with AML 45 or Ph þ ALL respectively. 39 Cytokines, such as IL-2, combined with DLI have resulted in complete responses in a proportion of patients failing to respond to DLI alone. 74 DLI depleted of CD8 þ cells or alloreactive T cells have been used with some success in other diseases 75, 76 with reductions in the incidence of GvHD, but data in acute leukaemia are not available. Other approaches include the blockade of CTLA-4 (a negative regulator of T cells) by a neutralizing human monoclonal antibody (ipilimumab). 77 There is some evidence that DLI collected after mobilization with G-CSF results in a reduction of GvHD without a loss of GvL. 78 This approach has been used with some success, even in the setting of haploidentical transplants, particularly if post-DLI immunosuppression is given in addition. 79 Novel immunotherapeutic strategies will be required in patients who relapse following cord blood (CB) transplants. One such approach is the use of small numbers of stem cells (such as may be obtained from 'washing' the CB unit bag post-infusion) to generate substantial numbers of cytokine-induced killer cells, which may be infused if the patient relapses, and have been shown to have strong anti-tumour activity. 80 Second allografts. There are several reports considering the outcome of a second allograft using myeloablative conditioning for patients with relapsed leukaemia (summarized in Table 2) . 41, [81] [82] [83] In these studies the TRM and relapse risk is often high. Favourable prognostic factors have differed between studies, which may in part be explained by differences in the study groups (for example age, prior conditioning regimen and so on).
Most recently, IBMTR 41 reported the outcomes in 197 patients with acute leukaemia (125 AML and 72 ALL) who relapsed following an HLA-matched sibling allograft. The probability of OS was 41 and 28% at 1 and 5 years respectively. At the same time points the TRM was 26 and 30%. Favourable factors were an age of o20 and a time to relapse of 46 months. The relapse risk was 42% at 5 years and was higher in those with a short time to relapse and/or not in remission at the second transplant. The presence of acute but not chronic GvHD following the second allograft significantly reduced the relapse rate. In this study results were comparable in AML and ALL (3-year OS of 27 and 30% respectively). There was no evidence in this study that the use of a different donor for the second allograft resulted in improved outcomes compared to those when the same donor was used.
The EBMT 81 presented outcome data on 170 patients receiving second allografts for relapsed leukaemia (including similar numbers with AML and ALL). The factor most significantly associated with an improved OS was the disease status at second allograft. Other factors which impacted favourably (both on OS and TRM) were a longer time to relapse after first allograft (with 292 days as the cutoff), use of TBI at second allograft and the absence of acute GvHD after the first allograft. The factors that were associated with a lower risk of relapse were longer duration of remission after first allograft, use of bone marrowderived stem cells (compared to peripheral blood-derived stem cells), CR at second transplant and acute GvHD. The Societe Francaise de Greffe de Moelle reported that factors which correlated significantly with a better OS were younger age, relapse 41-year after first allograft, absence Table 2 The outcome of second allogeneic transplants for patients relapsing after a first transplant for acute leukaemia of acute GvHD, presence of chronic GvHD and the use of a female donor. 83 More recently the use of RIC for the second allograft has been explored, with the hope of decreasing the TRM significantly and thus allowing the GvL effect time to control the disease. [84] [85] [86] [87] These studies all include small numbers of patients (summarized in Table 2 ). There appears to be an overall reduction in TRM compared to myeloablative transplants, however possibly an increase in relapse, and therefore similar survival overall.
The IBMTR study 41 included 45 patients who had RIC second allografts. The only significant impact of RIC compared to myeloablative conditioning was a higher relapse risk (RR ¼ 1.89). A study by Pawson et al. 84 reported the outcomes in 14 patients treated with a fludarabine and high-dose cytarabine containing conditioning regimen for relapse following a sibling allograft. This approach was well tolerated with no treatment-related deaths. Of the 14 patients, 13 achieved a CR and OS was 60% at 58 months. A study performed by the British Society for Blood and Marrow Transplantation 85 analysed the outcome in 39 patients with AML (n ¼ 25) and ALL (n ¼ 14). The group included adults and children and the donor was an HLA-identical sibling in 24, unrelated donor in 14 (3 mismatched) and 1 was a mismatched relative. The majority 34 received a myeloablative transplant as the first procedure, 59% including TCD in the protocol. The second allograft was performed using fludarabine-based RIC in most cases. The OS at 2 years was 21% in AML and 22% in ALL. At the corresponding time point the relapse risk and TRM in AML were 48 and 34% and in ALL were 52 and 30%. No factors impacted significantly on OS in univariate analysis, however the best outcome was seen in those patients who developed acute GvHD following the second transplant (31 versus 13%).
Cytokines. While the use of post-transplant cytokines is well defined for some disease entities (for example CML, myeloma) this is not the case for patients with acute leukaemia. Case reports and some small series are published which have analysed the effects of IFN-a, IL-2 and G/GM-CSF. 43, 88, 89 The mechanisms of action in this setting are not completely understood, but may include activation of dendritic cells, T cells and/or natural killer cells.
Most recently, promising results have been reported in a small number of patients treated with a combination of GM-CSF and IFN-a. 43 Of the seven patients who relapsed, 71% achieved a CR and the median OS was 442 days with three remaining alive between 400 and 1272 days. Five of these patients developed GvHD. These results compared favourably to other interventions in this institute (including second allografts and DLI); however it is not possible to exclude a selection bias in these patients.
Palliative
In some patients further treatment of the leukaemia may be inappropriate, whether due to the condition of the patient, the aggressiveness of the leukaemia (for example early relapse post-transplant, adverse cytogenetics) or patient choice. These patients should be offered support and palliation with the input of the multidisciplinary team.
Indeed, even where treatment is offered, a frank and honest discussion with the patient and their carers should be initiated at the outset to prepare the patient for the potential risks and benefits of the treatment. Realistically outlining the chances of success with individual treatments is important before patients can make an informed decision to progress with treatment or not.
Discussion
It is now clear that active treatment for patients with leukaemia relapsing after an allograft will result in ongoing remissions and potentially cure in a proportion of patients (20-50%). Many questions however remain unanswered, two key questions being which patients will benefit from treatment and which treatment approach (or combination of approaches) will be associated with the best outcomes.
The available evidence suggests that approaches that incorporate a strategy to enhance GvL have a superior outcome to those that do not.
In AML, recent reports on the success of DLI are encouraging, achieving OS of up to 50% in selected patients. These results appear to be best following remission induction chemotherapy. This equates approximately with the results of second allografts (OS up to 40%). Conversely, the results of DLI in ALL remain poor and there is some evidence that a second allograft (with OS of 20-30%) results in a superior outcome. 41, 81, 85 Whether using either myeloablative or RIC, second allografts are an acceptable and promising approach in patients relapsing 46 months after the first allograft. The use of RIC appears to be associated with a reduced TRM, without an obvious increase in the relapse risk, but also without a clear survival advantage at the time points reported. Clearly the follow-up of RIC transplants is short and more data are required, however the evidence that this approach is associated with a low TRM makes it an attractive approach for second transplants.
Certain factors have been identified which predict for a superior outcome (of DLI or second allograft), but these are not homogenous between the studies. The most important factor is the length of time from first allograft to disease relapse. The age of the patient is important in some studies but not others. Likewise the data on the impact of GvHD are conflicting, most likely due to the disparities between the cohorts. There is evidence in some studies that CR at second transplant results in better survival, 81, 90, 91 however this is not universally the case 84, 85 nevertheless our preferred strategy has been to attempt reinduction therapy prior to second transplant or DLI. In addition, it is not clear whether DLI and second allografts can be successfully combined to improve outcome. Certain situations may suggest one form of treatment over the other. For example, an allograft may be preferred in patients who are cytopenic or have had only partial responses to re-induction chemotherapy, alternatively DLI might be considered for patients with comorbidities or poor performance status who would be predicted to have a high TRM following a second transplant.
Any strategy that requires an infusion of donor cells will necessarily impact on the donor too. It is the policy of most registries to counsel donors at the time of original donation about the possibility of re-donating at a later time point. Despite this, donor willingness cannot be assumed. It may be that in particular transplant settings, consideration should be given to requesting permission to cryopreserve excess stem cells obtained at the original harvest. In view of the fact that the use of a different donor does not result in a worse outcome following a second allograft, this should be considered if the original donor is no longer available (or in patients who have received CB as the initial source of stem cells).
An attractive approach to prevent overt relapse is the use of focussed and early MRD surveillance, with active intervention with DLI in patients who are persistently MRD positive. Other promising approaches include modified DLI, combination of pharmaceutical agents with an immunological approach and cytokine therapy, but the data are currently few.
There is no doubt that this is an area of transplantation medicine that warrants urgent investigation. The challenge facing us is to construct well-planned, national and international, randomized trials and clinical studies, which aim to recruit large numbers of patients. The questions to be addressed should attempt to define the best combination of known approaches as well as how to combine novel therapies with these to improve patient outcomes. 
